Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

2004년 상반기에 부산 지역 소아에서 유행한 독감에서 Oseltamivir의 치료 효과

Clinical Effects of Oseltamivir in Children with Influenza in Busan, in the First Half of 2004

  • 투고 : 2004.11.24
  • 심사 : 2005.06.20
  • 발행 : 2005.09.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 인플루엔자는 소아 호흡기 질환의 중요한 원인이 되고 있으며, 심각한 합병증과 사망률을 가진다. 예방 및 치료를 위해 효과적인 항바이러스제 치료가 필요하지만 소아에서 항바이러스제 치료는 일반적이지 않으며, 그에 대한 자료도 부족한 실정이다. 본 연구에서는 neuraminidase의 억제제로서 인플루엔자 A와 B 바이러스에 모두 효과를 가지는 경구 oseltamivir의 효과에 대해 연구함으로써 앞으로 소아의 인플루엔자 치료에 있어서의 도움을 제공하려 한다. 방 법 : 2004년 1월부터 6월까지 부산 메리놀병원 외래, 입원 및 응급실 방문 환아 중 인플루엔자 바이러스 감염이 의심이 되는 환아 621명에서 인후도찰물 및 콧물을 채취하여 인플루엔자 바이러스 배양을 실시하였고, QuickVue test를 시행하였다. QuickVue test에 양성을 보인 181명의 환아들을 oseltamivir를 사용한 군과 사용하지 않은 군으로 나누었고, 이들의 임상 양상과 진단을 비교함으로써 oseltamivir의 치료 효과에 대하여 후향적으로 조사, 분석하였다. 결 과 : 연구기간 동안 621명의 인플루엔자 의심 환아 중 79 명(17.2%)에서 인플루엔자 바이러스가 분리되었고, QuickVue 인플루엔자 테스트에 양성을 보인 환아는 181명이었다. QuickVue 인플루엔자 테스트에 양성을 보인 181명 중 83명에서 oseltamivir를 5일간 하루 2회 사용하여 oseltamivir 사용군으로, 98 명은 증상 완화제만을 사용하여 oseltamivir 비사용군으로 정하였다. 두 집단간에 임상 증상과 진단은 차이가 없었고, oseltamivir 사용군에서 발열 기간의 의미 있는 감소를 확인할 수 있었다. 본 연구 기간 동안에는 인플루엔자 감염으로 인해 구토나, 구역, 복통을 호소하는 경우는 있었지만, 약물 투여로 인해 이들 증상이 악화되거나, 그로 인해 약물을 중단한 경우는 1례도 없었다. 결 론 : 본 연구 결과를 통해 소아에서 인플루엔자 치료에 oseltamivir를 사용함으로써 부작용 없이 발열 기간과 다른 호흡기 증상을 감소시킬 수 있음을 알 수 있다.

Purpose : Although influenza is one of the most important causes of acute respiratory tract infections in children, effective antiviral therapies are not common and there are only a few clinical studies on treatment of influenza in children. We evaluated the efficacy of oseltamivir in the treatment of naturally aquired influenza in children during the first half of 2004 in Busan. Methods : From January 2004 to June 2004, throat swabs and nasal washes were performed and cultured for the isolation of influenza virus and tested by rapid antigen detection test(QuickVue influenza test) in children with suspected influenza infections. The children who responded positively to the QuickVue influenza test, we divided into two groups : an oseltamivir treatment group and a control group. We compared their clinical symptoms(including fever duration) and diagnosis. The medical records of patients with influenza virus infection were reviewed retrospectively. Results : A total of 621 individuals were suspected of influenza infection. Influenza viruses were isolated in 79(17.2 percent) out of 621 patients examined. QuickVue influenza tests were positive in 181 cases. The treatment group(83 individuals) received oseltamivir twice daily for 5 days, and the control group(99 individuals) were administered only symptom relief medicine. There was no differences between the two groups in clinical diagnosis and symptoms. Oseltamivir treatment reduced the fever duration and other respiratory symptoms. There were no adverse events associated with oseltamivir treatment. Conclusion : Our data suggest that oral oseltamivir treatment reduces the fever duration and other respiratory symptoms of acute influenza without side effects in children.

키워드

참고문헌

  1. Glezen WP. Influenza and hospitalizations in children. N Engl J Med 2000;342:1752-3 https://doi.org/10.1056/NEJM200006083422313
  2. Simonsen L, Fukuda K. The impact of influenza on hospitalization. J Infect Dis 2000;181:831-7 https://doi.org/10.1086/315320
  3. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza : a randomized, controlled trial. JAMA 2000;283:1016-24 https://doi.org/10.1001/jama.283.8.1016
  4. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000;343:1778-87 https://doi.org/10.1056/NEJM200012143432407
  5. Nicholson KG, Aoki FY, Ostelhaus ADME, Trottier S, Carexicz O, Mercier H, et al. Efficacy and safety of oseltamivir in treatment of acute influenza : a randomized, controlled trial. Lancet 2000;355:1845-50 https://doi.org/10.1016/S0140-6736(00)02288-1
  6. Hayden FG, Atmar RL, Schilling M, Johnson C. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43 https://doi.org/10.1056/NEJM199910283411802
  7. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, et al. A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population. Zhonghua Jie He He Hu Xi Za Zhi 2004;27:455-9
  8. Bettes R, Mandell GL, Bennet J, Dolin R. Principles and practice of infectious disease. 4th ed. New York : Churchill Livingstone Inc. 1995:1546-67
  9. Wrigh P, Behrman RE, Kliegman RM, Jenson HB. Nelson textbook of pediatrics. 16th ed. philadelphia : WB Saunders Co, 2000:987-90
  10. Vtakova T, Nermut MV, Hay AJ. The NB protein is an integral component of the membrane of influenza B virus. J Gen Virol 1996;77:1689-94
  11. Choi YH. Prevention and treatment of influenza. J Korean Med Assoc 2002;45:1487-95
  12. Schmidt AC. Antiviral therapy for influenza : a clinical and economic comparative review. Drugs 2004;64:2031-46 https://doi.org/10.2165/00003495-200464180-00003
  13. Centers for Disease Control and Prevention. Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR 1998; 48:1-28
  14. Hall CB, Dolin R, Gala CL. Children with influenza A infection : treatment with rimantadine. Pediatrics 1987;80:275-82
  15. Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, Giodani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981;19:226-33 https://doi.org/10.1128/AAC.19.2.226
  16. Hayden FG, Belshe RM, Clover RD, May AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702. https://doi.org/10.1056/NEJM198912213212502
  17. Hyden FG, Osterhaus ADME, Treanor JJ, Felming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-80 https://doi.org/10.1056/NEJM199709253371302
  18. MIST. Randomized trial of efficiacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. N Engl J Med 1998;352:1877-81
  19. Englund JA. Antiviral therapy of influenza. Semin Pediatr Infect Dis 2002;13:120-8 https://doi.org/10.1053/spid.2002.122999
  20. Mcclellan K, Perry CM. Oseltamivir : A review of its use in influenza. Drugs 2001;61:263-83 https://doi.org/10.2165/00003495-200161020-00011
  21. Quach C, Newby D, Daoust G, Rubin E, McDonald J. QuickVue influenza test for rapid detection of influenza A and B viruses in a pediatric population. Clin Diagn Lab Immunol 2002;9:925-6
  22. Poehling KA, Griffin MR, Daoust G, Rubin E, McDonal J. QuickVue influenza test for the rapid detection of influenza A and B viruses in a pediatric population. Clin Diagn Lab Immunol 2002;9:925-6
  23. Yamazaki M, Mitamura K, Kimura K. Clinical evaluation of an immunochromatography test for rapid diagnosis of influenza. Kansenshogaku Zasshi 2001;75:1047-53
  24. Kawakami C, Shimizu H, Watanabe S. Evaluation of immunochromatography method for rapid detection of influenza A and B viruses in Japanese. Kansenshogaku Zasshi 2001;75:792-9
  25. Uyeki TM. Influenza diagnosis and treatment in children : a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22:164-77
  26. Doller G, Tjhen KY, Schuy W, Gerth HJ. Rapid diagnosis of influenza virus infections from nasopharyngeal secretions. Monatsschr Kinderheilkd 1991;139:287-91
  27. Lee PY, Matchar DB, Clements D, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002;137:225-31 https://doi.org/10.7326/0003-4819-137-4-200208200-00005
  28. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001;33:1879-85 https://doi.org/10.1086/324491
  29. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002;113:300-7 https://doi.org/10.1016/S0002-9343(02)01222-6
  30. Mitamura K, Sugaqa N, Nirasawa M, Shinjoh M, Takeuchi Y. Effectiveness of oseltamivir treatment against influenza type A and type B infection in children. Kansenshogaku Zasshi 2002;76:946-52
  31. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age : cost effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139:321-9
  32. Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Pediatr Drugs 2001;3:229-30 https://doi.org/10.2165/00128072-200103030-00005
  33. Aoki FY. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123-9 https://doi.org/10.1093/jac/dkg007
  34. Kashiwagi S. Criteria for the use of antiinfluenza agent. Nippon Rinsho 2003;61:1963-6
  35. Kawai N. Iwaki N, Kawashima T, Satoh I, Tsuchimoto T, Shigematsu T, et al. Effectiveness of oseltamivir on influenza and influencing factors : age of patients, type of influenza virus and timing of initial administration. Kansenshogaku Zasshi 2003;77:428-9
  36. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir : descriptive study. Lancet 2004;364:759-65 https://doi.org/10.1016/S0140-6736(04)16934-1
  37. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at His 274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002;46:3809-16 https://doi.org/10.1128/AAC.46.12.3809-3816.2002
  38. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir Res 2002;54:79-88 https://doi.org/10.1016/S0166-3542(01)00215-7